Article
Endocrinology & Metabolism
Yan-Song Lin, Hui Yang, Yong Ding, Yi-Zhuang Cheng, Feng Shi, Jian Tan, Zhi-Yong Deng, Zhen-Dong Chen, Rong-Fu Wang, Qing-Hai Ji, Rui Huang, Lin-Fa Li
Summary: The study evaluated the efficacy and safety of the new multikinase inhibitor donafenib in treating locally advanced or metastatic RAIR-DTC. Both 200mg and 300mg doses of donafenib showed similar efficacy in terms of objective response rate, with the 300mg dose demonstrating a trend towards longer progression-free survival and more tumor shrinkage. The most common grade 3 treatment-related adverse events were palmar-plantar erythrodysesthesia and hypertension.
Article
Endocrinology & Metabolism
Myat Han Soe, Janet M. Chiang, Robert R. Flavell, Elham Khanafshar, Laura Mendoza, Hyunseok Kang, Chienying Liu
Summary: Patients with radioactive iodine refractory metastatic differentiated thyroid cancer have a poor prognosis. This study aimed to characterize patients with non-iodine-avid disease at diagnosis. The results showed that non-iodine-avid disease is highly prevalent in DTC patients with BVL cancers, particularly with BRAF (V600E) and TERT promoter mutations, and is associated with older age.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang, Shenghai Xing
Summary: This study evaluated the cost-effectiveness of apatinib and cabozantinib for RAIR-DTC from the perspective of the Chinese healthcare system. The results showed that apatinib is cost-effective compared to placebo, while cabozantinib may not be cost-effective and a reduction in price is warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Yuanna Ling, Xiaoli Xiong, Jiaxin Luo, Quanliang Zou, Pan Chen, Liqin Pan, Man Long, Huijuan Feng, Wei Ouyang
Summary: This study aims to demonstrate the clinical efficacy and safety of sorafenib used in the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC) at Zhujiang Hospital of Southern Medical University. The results showed that sorafenib has promising efficacy in RR-DTC, especially in patients with lung metastasis and lung-only metastasis. The main adverse effect of sorafenib was hand-foot skin syndrome (HFS).
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Jinyan Chai, Ruiguo Zhang, Wei Zheng, Guizhi Zhang, Qiang Jia, Jian Tan, Zhaowei Meng, Renfei Wang
Summary: This study evaluated the predictive value of clinical and pathological characteristics for metastatic RAIR-DTC, finding that factors such as age, extrathyroid invasion, gene mutations, and response to RIT could predict the risk of RAIR-DTC in both TgAb-negative and TgAb-positive patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Marcia S. S. Brose, Johannes W. A. Smit, Chia-Chi Lin, Masayuki Tori, Daniel W. W. Bowles, Francis Worden, Daniel Hueng-Yuan Shen, Shih-Ming Huang, Hui-Jen Tsai, Maria Alevizaki, Robin P. P. Peeters, Shunji Takahashi, Pavel Rumyantsev, Rongjin Guan, Svetlana Babajanyan, Kirhan Ozgurdal, Iwao Sugitani, Fabian Pitoia, Livia Lamartina
Summary: Sorafenib and lenvatinib are approved for RAI-R DTC, but there is no consensus on when to initiate MKI treatment. This study evaluated TTSP in patients with RAI-R DTC for whom the decision to treat with an MKI was made at study entry. The results showed that most patients had a TTSP of 36 months or more, indicating a positive impact of MKIs on patient prognosis.
Review
Oncology
Michele Klain, Emilia Zampella, Carmela Nappi, Emanuele Nicolai, Raffaele Ambrosio, Elena Califaretti, Livia Lamartina, Martin Schlumberger, Desiree Deandreis, Domenico Salvatore, Alberto Cuocolo
Summary: This review summarizes recent advances in functional imaging and theragnosis of DTC, focusing on the use of radioactive iodine for treatment and FDG uptake for diagnosis. It also discusses other potential tracers and technologies that may offer new opportunities in selecting specific imaging modalities or treatments for patients with DTC.
Article
Oncology
Canhua Yun, Juan Xiao, Jingjia Cao, Chunchun Shao, Lihua Wang, Wei Zhang, Hongying Jia
Summary: The study analyzed 1228 patients who received RAI treatment and found that LNMs and LNR are important predictors for initial response to RAI, with optimal cutoff values of 5 and 0.30, respectively.
Article
Endocrinology & Metabolism
Bernadette L. Dekker, Mirthe H. Links, Anneke C. Muller Kobold, Linda G. Swart-Busscher, Marleen Kars, Judith A. P. Bons, Adrienne H. Brouwers, Thera P. Links, Anouk N. A. Van der Horst-Schrivers
Summary: This study investigated whether a 4-day low-iodine diet (LID) is sufficient for adequate iodine depletion in differentiated thyroid cancer (DTC) patients preparing for I-131 therapy. The results showed no significant difference in the 24-hour urinary iodine excretion (UIE) between day 4 and day 7 of the LID. On day 4, 72.1% of DTC patients achieved adequate preparation, increasing to 82.0% on day 7. Compared to their regular diet, DTC patients had significantly lower nutrient intake during the LID.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Liu Xiao, Wenjie Zhang, Hongmei Zhu, Yueqi Wang, Bin Liu, Rui Huang, Lin Li
Summary: This study investigated the changes in PTH, serum calcium, phosphorus, and 25-OH-VD levels before and after RAI in DTC patients, finding that about one-fifth of patients may experience hypocalcemia at five days post-RAI. Lower baseline pre-RAI serum calcium and PTH levels, as well as negative (TcO4)-Tc-99m (-) thyroid imaging, were identified as risk factors for hypocalcemia at five days post-RAI.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Otorhinolaryngology
Stylianos Monos, Christian Fritz, Jacob Harris, Dominic Romeo, Jinggang J. Ng, Katherine Xu, Benjamin Cooperberg, Alvaro Moreira, Karthik Rajasekaran
Summary: This study assessed and evaluated clinical practice guidelines for radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC), as well as the treatment for radioactive iodine refractory (RAI-R) DTC. The findings revealed a lack of high-quality guidelines in both areas and highlighted the need for more rigorously developed guidelines to guide the use of RAI in DTC and the treatment for RAI-R DTC.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
(2023)
Article
Endocrinology & Metabolism
Lauren P. Wallner, Mousumi Banerjee, David Reyes-Gastelum, Ann S. Hamilton, Kevin C. Ward, Carrie Lubitz, Sarah T. Hawley, Megan R. Haymart
Summary: The study examined factors at both patient and physician levels that influence the use of radioactive iodine (RAI) for low-risk thyroid cancer. Physicians' perspectives and attitudes, as well as patient volume, were found to significantly affect the use of RAI in low-risk thyroid cancer cases. Efforts to reduce overuse of RAI should be directed towards interventions targeted at physicians in addition to patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Timothy M. Ullmann, Maria Papaleontiou, Julie Ann Sosa
Summary: This review discusses the controversies and difficult decisions in the management of low-risk differentiated thyroid cancer (DTC) and provides recommendations. While overdiagnosis is a concern, the true incidence of DTC has also increased. Treatment options vary, and personalized and nuanced treatment decisions are necessary for clinicians and patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Oncology
Xiaoran Mei, Xiaoqin Yao, Fang Feng, Weiwei Cheng, Hui Wang
Summary: This study found that DTC survivors had a slightly increased risk of developing other malignancies after receiving RAI treatment, but the attributable risk proportion associated with RAI was relatively low, indicating a low absolute number of malignancies induced by RAI in DTC survivors. The highest attributable risk proportion of RAI treatment was observed in hematological malignancies, but due to their low incidence among all DTC survivors, the absolute number of hematological malignancies was low.
Article
Endocrinology & Metabolism
Stephanie Davis, Timothy M. Ullmann, Sanziana Roman
Summary: This review examines the disparities in diagnosis and treatment of patients with differentiated thyroid cancer (DTC) and proposes practical clinical and policy ideas for improving the gap in treatment.
